在疹脑炎中使用阿西克洛维尔的剂量策略:回顾图表回顾图表
Asma Aboelezz1, Maged Kharouba1, Sherif Hanafy Mahmoud1
1Faculty of Pharmacy and Pharmaceutical Sciences, College of Health Sciences, University of Alberta, Edmonton, Alberta, Canada.
概括
优化阿西克洛维尔剂量对于疹脑炎至关重要. 根据体重的适当剂量可以改善患者的康复并预防急性损伤 (AKI),但需要进一步的多中心研究.
科学领域:
- 神经学 神经学
- 传染性疾病 传染性疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 疹脑炎是一种关键的大脑炎症,需要立即使用阿西克洛维尔进行抗病毒治疗.
- 早期服用阿西克洛维尔对于减少神经损伤和提高生存率至关重要.
- 该研究调查了疹脑炎患者的阿西克洛维尔剂量,以评估安全性和有效性.
研究的目的:
- 描述疑似或确诊的疹脑炎患者的阿西克洛维尔剂量方案.
- 确定阿西克洛维尔剂量与患者结果之间的关联,包括恢复和急性损伤 (AKI).
主要方法:
- 在阿尔伯塔大学医院对237名患者进行了回顾性观察性研究.
- 对人口统计,并发症,并发药物和阿西克洛维尔剂量等患者病历的审查.
- 使用回归建模分析有效性 (完全恢复,部分恢复,死亡) 和安全性 (AKI) 结果.
主要成果:
- 在接受阿西克洛维尔治疗超过2天的患者中,57%的患者获得了足够的剂量;35%的患者获得了亚治疗剂量.
- 亚治疗性阿西克洛维尔剂量与更糟糕的结果有关,特别是单纯疹病毒1型 (HSV-1).
- 超治疗性阿西克洛维尔剂量显著增加了急性损伤 (AKI) 的风险.
结论:
- 根据实际体重 (非肥胖) 和理想体重 (肥胖) 调整的阿西克洛维尔剂量可以改善结果并防止毒性.
- 需要进行更多的多中心前性研究来验证这些发现,并建立针对疹脑炎的最终剂量指南.
相关概念视频
01:10Retrovirus Life Cycles
45.5K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
45.5K
01:15Drug Dosage Regimen: Overview
3.4K
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
3.4K
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
200
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
200